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ABSTRACT 
The therapeutic potential of tocotrienol, a member of the vitamin E family of compounds 
with potent in vitro anti-cancer properties, is limited by its inability to specifically reach 
tumors following intravenous administration. The purpose of this study is to determine 
whether a novel tumor-targeted vesicular formulation of tocotrienol would suppress the 
growth of A431 epidermoid carcinoma and B16-F10 melanoma in vitro and in vivo.  
In this work, we demonstrated that novel transferrin-bearing multilamellar vesicles 
entrapping Į-T3 resulted in a dramatically improved (by at least 52-fold) therapeutic 
efficacy in vitro on A431 cell line, compared to the free drug. In addition, the intravenous 
administration of tocotrienol entrapped in transferrin-bearing vesicles resulted in tumor 
suppression for 30% of A431 and 60% of B16-F10 tumors, without visible toxicity. Mouse 
survival was enhanced by more than 13 days compared to controls administered with the 
drug solution only.  
This tumor-targeted, tocotrienol-based nanomedicine therefore significantly improved the 
therapeutic response in cancer treatment. 
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1. Introduction 
Tocotrienol, a member of the vitamin E family of compounds, is currently receiving 
increased attention because of its promising anti-tumor activity [1,2]. It has been reported 
to exert its anti-cancer effects through various mechanisms, such as activation of p53, 
modulation of Bax/Bcl-2 ratio, decrease of oxidative stress and induction of apoptosis [1-
4]. It can also inhibit angiogenesis by downregulating the expression of the vascular 
endothelial growth factor (VEGF) receptor and blocking intracellular VEGF signaling. In 
addition, it is able to potentiate apoptosis through inhibition of DNA polymerase and 
telomerase and of NF-ț%DFWLYDWLRQSDWKZD\>-4]. This wide range of anti-cancer effects 
therefore makes tocotrienol a very promising therapeutic molecule. 
However, its efficacy against cancer cells in vivo is hindered by its inability to specifically 
reach cancer cells at a therapeutic concentration, without affecting normal cells. Given its 
anti-proliferative properties, it is of the utmost importance to find a strategy to deliver this 
therapeutic drug specifically to its site of action. 
On the basis that iron is essential for tumor cell growth and can be effectively carried to 
tumors by using transferrin receptors overexpressed on cancer cells [5,6], we recently 
demonstrated that the conjugation of transferrin (Tf) to vesicles entrapping tocotrienol-rich 
fraction (TRF) extracted from palm oil could lead to tumor regression, and even tumor 
suppression, on both the tested cancer cell lines, following intravenous injection to a 
murine model [7-9]. It resulted in complete tumor eradication for 50% of B16-F10 tumors 
and 20% of A431 tumors [7]. The treatments were well tolerated by the animals, without 
weight loss or apparent signs of toxicity. 
These previous studies, however, used TRF but did not evaluate the anti-cancer potency 
of each individual tocotrienols and tocopherols IRUPLQJ75)ZKLFKLVDPL[WXUHRIĮȖ-į-
WRFRWULHQRO Į-tocopherol and other tocotrienol-related compounds. Structurally, 
tocotrienols and tocopherols consist of a chroman ring linked to a phytyl side chain, which 
is saturated only for tocopherols. Furthermore, tocotrienols and tocopherols compounds 
differ in the number and position of methyl substituents attached to their chroman ring [10]. 
Hence, the therapeutic efficacy resulting from tocotrienol formulations could be further 
enhanced by entrapping only the most effective tocotrienol compound(s) within optimized 
tumor-targeted vesicles. 
The objectives of this study are therefore 1) to evaluate the efficacy of the individual 
tocotrienols and tocopherols entrapped in transferrin-bearing vesicles against the in vitro 
viability of various cancer cells and 2) to optimize the delivery system carrying tocotrienol 
by a) increasing the amount of drug entrapped within the vesicles, b) optimizing the 
amount of transferrin grafted to the vesicles and c) optimizing the overall structure of the 
vesicles. 
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2. Materials and methods 
2.1. Cell lines and reagents 
Į-WRFRWULHQROĮ-7Ȗ-WRFRWULHQROȖ-7į-WRFRWULHQROį-7Į-WRFRSKHUROĮ-Toc), human 
holo-transferrin, dimethylsuberimidate and all other chemicals that are not specifically 
mentioned below were purchased from Sigma Aldrich (Poole, UK). Solulan C24 came from 
Amerchol (Edison, NJ). D-Į-tocopheryl polyethylene glycol 1000 succinate (TPGS) was 
obtained from Eastman Chemical Company (Kingsport, TN). A431 human epidermoid 
carcinoma and Bioware® B16-F10-luc-G5 mouse melanoma that expresses the firefly 
luciferase, were respectively purchased from the European Collection of Cell Cultures 
(Salisbury, UK) and Caliper Life Sciences (Hopkinton, MA). DMEM and RPMI-1640 cell 
culture media, fetal bovine serum, L-glutamine and penicillin-streptomycin were obtained 
from Invitrogen (Paisley, UK). Passive lysis buffer came from Promega (Southampton, 
UK). 
 
2.2. Preparation and characterization of transferrin-bearing vesicles entrapping tocotrienol 
and tocopherol compounds 
To prepare control vesicles entrapping tocotrienol (T3) and tocopherol (Toc), a mixture of 
Span 60 (65 mg), cholesterol (58 mg), Solulan C24 (54 mg) in a solution of eitheUĮ-7Ȗ-
7į-7RUĮ-Toc (1 mg/mL, prepared in 0.2 mL dimethylsulfoxide and 1.8 mL glucose 5% 
solution) was shaken at 60 oC for 1 hour, before being probe sonicated with a Soniprep 
150 (MSE, London, UK) for 4 min. Tf-bearing vesicles were then prepared by conjugating 
Tf (12 mg) to the control vesicles (2 mL), using dimethylsuberimidate as a cross-linker, as 
previously described [7-9]. Unentrapped T3 or Toc was removed by ultracentrifugation 
(150 000 g for 1h). The vesicle pellet was then resuspended in 2 ml glucose 5% solution.  
Vesicles were visualized by transmission electron microscopy (TEM) on a LEO 912 energy 
filtering electron microscope (Zeiss, Jena, Germany), as previously described [11]. 
T3 and Toc entrapment in the vesicles was quantified by spectrofluorimetry using a Varian 
Cary Eclipse spectrofluorometer (Palo Alto, CA) following disruption of the vesicles with 
isopropanol. To do so, 50 µL of the vesicles prepared above were diluted 1:100 with 
isopropanol, before fluorescence intensity was measured using thHUHVSHFWLYHȜex DQGȜem 
RIWKHFRPSRXQGVȜexQPIRUĮ-7DQGĮ-7RFQPIRUȖ-7DQGį-7Ȝem: 327 nm 
IRUĮ-T3, 330 nm for the 3 other compounds). 
The amount of transferrin present on the surface of the vesicles was measured by Lowry 
assay [12].  
Size and zeta potential of the vesicles were respectively determined by photon correlation 
spectroscopy and laser Doppler electrophoresis on a Zetasizer Nano-ZS (Malvern 
Instruments, Malvern, UK). 
 
2.3. In vitro biological characterization 
2.3.1. Cell culture  
A431 and B16-F10-luc-G5 cell lines were respectively grown in DMEM or RPMI-1640 
medium supplemented with 10% (v/v) fetal bovine serum, 1% (v/v) L-glutamine and 0.5% 
(v/v) penicillin-streptomycin. Cells were cultured at 37oC in a humid atmosphere of 5% 
CO2. 
 
2.3.2. Efficacy against cancer cell viability 
The efficacy of T3 and Toc entrapped in Tf-bearing vesicles, control vesicles or in solution 
against cancer cell viability was assessed in A431 and B16-F10 cell lines. Cells (2 x 103 
cells per well in 96-well plates seeded 72 hours prior treatment) were incubated for 72 
hours with T3/Toc formulations at final concentrations of 1.28 × 10-3 WRȝJP/GUXJ
The activity of the formulations against cell viability was evaluated by measurement of the 
growth inhibitory concentration for 50% of the cell population (IC50) in a standard MTT cell 
viability assay based on cellular metabolic activity (n=15). 
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2.3.3. Analysis of cellular uptake 
Qualitative analysis of cellular uptake was performed by coherent anti-Stokes Raman 
scattering (CARS) microscopy. A431 cells were seeded in 4-well chamber slides at a 
concentration of 104 cells/ well. After 72 hours, they were incubated fRUKRXUVZLWKĮ-T3 
(0.2 µg/well), either entrapped in Tf-bearing vesicles, control vesicles or in solution. They 
were then washed three times with 1 mL PBS, fixed with 1 mL methanol for 10 minutes 
and finally washed 3 times with 1 mL distilled water before being examined with a home-
made CARS microscope, as described before [13].  
 
2.4. Optimization of the tocotrienol formulations 
2.4.1. Combination therapy 
To assess if the efficacy of T3 and Toc vesicles against cancer cell viability could be 
increased by co-entrapment of various T3 and Toc compounds, two Tf-bearing vesicular 
formulations containing all four components of TRF in various ratios were prepared. 
)RUPXODWLRQV)DQG)FRQWDLQUHVSHFWLYHO\DQGRIĮ-T3 while the other three 
FRPSRQHQWVRI75)Ȗ-7į-7DQGĮ-Toc) were distributed in equal percentages in the 
IRUPXODWLRQ Ȗ-7į-7DQGĮ-7RFIRU)Ȗ-7į-T3 and 
Į-Toc for F75).  Both formulations contain 1 mg/mL T3 and Toc compounds for a 
total volume of 2 mL. Vesicle size, zeta potential, percentage of drug loading and efficacy 
against A431 cancer cells viability were determined and compared between the 
fRUPXODWLRQVHQWUDSSLQJĮ-T3. 
 
2.4.2. Drug loading 
Three Tf-bearing vesicular formulations were prepared as described above, with 
UHVSHFWLYHO\PJPJDQGPJĮ-T3 LQVWHDGRIPJĮ-T3.  
 
2.4.3. Amount of transferrin conjugated to the vesicles 
Various amounts of Tf (respectively 6, 18, 24 and 30 mg of Tf, and 12, 36, 48 and 60 mg 
of dimethylsuberimidate) was conjugated on four formulations of vesicles loaded with 2 mg 
Į-T3, prepared as described above.  
 
2.4.4. Replacement of unilamellar vesicles by multilamellar vesicles 
To evaluate if changes in the number of lipid bilayers forming the vesicles could increase 
the efficacy of T3 and Toc vesicles against cancer cell viability, new multilamellar vesicles 
HQWUDSSLQJĮ-7ZHUHSUHSDUHGĮ-T3 (2 mg) and TPGS (57 mg) in 2 mL distilled water 
were probe sonicated for 2 min, before being added to Span 60 (65 mg), cholesterol (58 
mg) and dioleoyl phosphatidylethanolamine (DOPE) (6 mg). The resulting mixture was 
shaken at 60oC for 1 h and then probe sonicated for 4 min. Tf-bearing vesicles were 
prepared by conjugating 12 mg Tf to 2 mL vesicles as described above for unilamellar 
vesicles.  
 
2.5. In vivo tumoricidal activity 
All animal experiments conducted were approved by the local ethics committee and 
performed in accordance with the UK Home Office regulations. Female, immunodeficient 
BALB/c mice (initial mean weight 20 g) were housed in groups of five with a room 
temperature of 21 ± 2°C and alternating 12h light-dark cycle. A431 or B16-F10-luc-G5 
cancer cells in exponential growth were subcutaneously implanted to both flanks of the 
mice (1 x 106 cells per flank). When tumors become palpable and reach a diameter of 5 
mm, the mice (n=5) were intravenously injected with T3 encapsulated in Tf-bearing 
vesicles, control vesicles or in solution (10 µg T3 per injection) once daily for 20 days. The 
mice were observed daily for tumor growth and body weight. The tumor volume was 
GHWHUPLQHGE\FDOLSHUPHDVXUHPHQWVDQGFDOFXODWHGE\WKHIRUPXOD³YROXPH G3 [ʌ´ 
Tumor growth was also monitored by bioluminescence imaging with an IVIS Spectrum 
(Caliper Life Sciences, Hopkinton, MA). Mice bearing subcutaneous B16-F10-luc-G5 
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tumors were treated intravenously as described above. Ten minutes prior to in vivo 
imaging, they received the luciferase substrate D-luciferin (150 mg/kg body weight) by 
intraperitoneal injection and were anaesthetized by isoflurane inhalation on Days 1, 3, 5 
and 7. The light emitted from the bioluminescent tumors was detected for 2 min using 
Living Image® software and displayed as a pseudo-color overlay onto a gray scale animal 
image. 
 
2.6. Statistical Analysis 
Results were expressed as means ± standard error of the mean (S.E.M). Statistical 
significance was assessed by one-way analysis of variance (ANOVA) (to determine 
whether there are any statistically significant differences between the means of three or 
more independent groups), followed by Tukey multiple comparison post-test (Minitab® 
software, State College, PE) (to determine which means amongst a set of means differs 
from the rest). Differences were considered statistically significant for P values lower than 
0.05. 
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3. Results  
3.1. Preparation and characterization of transferrin-bearing vesicles entrapping tocotrienol 
and tocopherol compounds 
Tf-bearing and control unilamellar vesicles entrapping tocotrienol compounds have been 
successfully prepared, as confirmed by TEM imaging (Fig. 1). These vesicles were able to 
HQWUDSRIĮ-7RIȖ-7RIį-T3 and 68.9 ± 3.1 % 
RIĮ-Toc. An amount of 10.1 ± 0.5 mg transferrin was conjugated to the vesicles, which 
corresponds to an increase compared to the conjugation of about 6 mg transferrin 
obtained in our previous studies [8]. As expected, the conjugation of Tf to the surface of 
the loaded vesicles resulted in a slightly larger z-average mean diameter of 133 nm 
(polydispersity: 0.20) than that of control vesicles (114 nm, polydispersity: 0.18). The 
grafting of Tf to the vesicles reduced their zeta potential compared to that of control 
vesicles (-30 mV and -25 mV respectively for Tf-bearing and control vesicles). 
 
 
 
 
 
Figure 1. Transmission electron micrograph images of Tf-bearing and control unilamellar 
YHVLFOHVHQWUDSSLQJĮ-7Ȗ-7į-7DQGĮ-Toc (Bar: 200 nm). 
 
  
3.2. In vitro efficacy against cancer cell viability 
The in vitro efficacy against cancer cell viability of T3 and Toc compounds was significantly 
improved when formulated in Tf-bearing vesicles, by up to 1.6-fold on B16F10 cells and up 
to 1.7-fold on A431 cells when compared to control vesicles (Table 1). Among all the 
IRUPXODWLRQV WHVWHG Į-7 DQG Į-Toc entrapped in Tf-bearing vesicles resulted in the 
highest efficacy on B16F10 cells, with IC50 respectively of 1.07 ± 0.07 and 1.06 ± 0.18 
JP/,Q$FHOOVKRZHYHURQO\Į-T3 in Tf-bearing vesicles led to the highest efficacy 
against cancer cell viability, with an IC50 of 0.57 ± 0.26 µg/mL. Most of the tocotrienol 
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compounds formulated as solutions did not exert any effect on cell viability for the 
experimental parameters and concentrations used, probably due to their failure to be taken 
up by the cancer cells.  
 
 
Table 1. Efficacy RI Į-7 Ȗ-7 į-7 DQG Į-Toc solutions against B16-F10 and A431 
cancer cell viability, expressed as IC50 values (n=15) 
B16F10 cells 
 
  Compound
 
IC50 (µg/mL) (mean ± S.E.M.)
 
Tf-vesicles
 
Control vesicles
 
Free drug
 
Į-T3
 
1.07 ± 0.07
 
1.23 ± 0.19
 
50.48 ± 0.12
 
Ȗ-T3
 
2.27 ± 0.39
 
2.97 ± 0.16
 
> 20
 
į-T3
 
1.29 ± 0.11
 
1.39 ± 0.20
 
> 20
 
Į-Toc
 
1.06 ± 0.18
 
1.71 ± 0.25
 
> 20
 
 
   
A431 cells 
 
  Compound
 
IC50 (µg/mL) (mean ± S.E.M.)
 
Tf-vesicles
 
Control vesicles
 
Free drug
 
Į-T3
 
0.57 ± 0.26
 
0.99 ± 0.06
 
> 20
 
Ȗ-T3
 
1.01 ± 0.15
 
1.33 ± 0.09
 
> 20
 
į-T3
 
1.73 ± 0.52
 
2.94 ± 0.14
 
14.73 ± 0.20
 
Į-Toc
 
1.13 ± 0.17
 
1.70 ± 0.48
 
> 20
 
 
 
3.3. Optimization of the tocotrienol formulation 
3.3.1. Combination therapy 
No significant changes in vesicle size or zeta potential were observed for Tf-bearing 
vesicles formulated as Formulations F25 and F75, which contain respectively 25% and 
 RI Į-7 ZKLOH WKH RWKHU WKUHH FRPSRQHQWV RI 75) Ȗ-7 į-7 DQG Į-Toc were 
distributed in equal percentages in the formulation, compared to Tf-bearing vesicles 
entrapping 100% RI Į-T3 (Table 2A). These formulations have an average size ranging 
IURPQP WRQP9DULDWLRQVRI WKHSHUFHQWDJHRIĮ-T3 entrapped in the 
formulation did not have an influence either on the charges of the vesicles (-32 ± 3 mV for 
F25, -29 ± 4 mV for F75, compared to -30 ± 2 mV for Tf-bearing vesicles entrapping 100% 
Į-T3). However, F25 and F75 formulations showed a much higher percentage of drug 
loading FRPSDUHGWRWKHIRUPXODWLRQFRQWDLQLQJĮ-T3 (respectively 74.4 ± 2.5%, 78.1 
± 0.5%, 69.9 ± 1.8% for F25, F75 and Tf-EHDULQJYHVLFOHVHQWUDSSLQJĮ-T3). This is 
possibly due to changes in overall lipophilicity, as F25 and F75 contains a mixture of T3 
and Toc compounds. Despite this increase in drug loading, the formulation leading to the 
highest efficiency against A431 cell viability remained Tf-bearing vesicles entrapping 100% 
Į-T3, which indicates that the presence of other compounds reduces the efficacy RIĮ-T3 
against cancer cell viability (Table 2A).  
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Table 2. Characteristics and efficacy RIĮ-T3 entrapped in Tf-bearing vesicles optimized by 
variation of the following parameters, against A431 cancer cell viability (n=15): 
A) vDULDWLRQRI WKHSHUFHQWDJHRIĮ-T3 co-entrapped in Tf-bearing vesicles with other 
T3 and Toc compounds (Total amount of T3 and Toc per formulation: 2 mg) 
B) variation of the amount of entrapped Į-T3 
C) variation of the amount of conjugated Tf to the vesicles 
D) replacement of unilamellar vesicles by multilamellar vesicles 
 
 
A 
 
 
 
 
 
 
 
 
Percentage of Average size Zeta potential Drug IC50  
 Į-T3
 
 (nm)
 
 (mV)
 
loading (%)
 
(µg/mL) 
 
25%
 
115 ± 3 -32  ± 3 74.4  ± 2.5 1.21  ± 0.12 
75%
 
113  ± 1 -29 ± 4 78.1  ± 0.5 1.27  ± 0.21 
100%
 
114  ± 2 -30  ±  2 69.9  ± 1.8 0.57  ± 0.26 
 
  
 
 B
 
 
 
 
 
 
 
 
Amount of  Drug Amount of  IC50  
 
Į-T3
 
loading entrapped (µg/mL) 
 
 
(mg)
 
(%)
 
drug (mg)
 
 
 
 
2 69.9  ±  1.8
 
1.40  ± 0.02
 
0.57 ± 0.26
 
 
4 63.5  ±  0.1
 
2.54 ± 0.01
 
3.50 ± 0.14
 
 
6 62.3  ±  0.6
 
3.74  ± 0.02
 
4.98 ± 0.33
 
 
8 71.7  ± 0.1
 
5.74  ± 0.01
 
5.06 ± 0.28
 
 
 
  
  C
 
 
 
 
 
 
 
 
Amount of  Amount of  Ligand IC50  
 
added Tf conjugated Tf
 
conjugation (µg/mL) 
 
 
 (mg)
 
(mg)
 
 (%)
 
 
 
 
6 5.2  ± 0.1
 
86.7  ± 2.3
 
0.95 ± 0.05
 
 
12 10.1  ± 0.5
 
84.2  ± 3.8
 
0.57 ± 0.26
 
 
18 15.0  ± 0.6
 
83.2  ± 3.6
 
0.92 ± 0.05
 
 
24 18.6  ± 0.4
 
77.3  ± 1.9
 
0.76 ± 0.03
 
 
30 19.3  ± 0.2
 
64.2  ± 0.6
 
0.80 ± 0.06
 
 
 
    
D
 
 
 
 
 
 
 
 
 
Type of  Average Zeta  Drug IC50  
vesicles
 
size (nm)
 
potential (mV)
 
loading (%)
 
(µg/mL) 
 
Tf-bearing MV 176 ±  1
 
-52  ± 3
 
69.9  ± 0.2
 
0.38 ± 0.07
 
Control MV 167  ± 1
 
-49  ± 2
 
69.2  ± 0.4
 
0.45 ± 0.06
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3.3.2. Drug loading 
7KH DPRXQW RI Į-T3 entrapped within Tf-bearing vesicles increased linearly with the 
increasing amounts of drug initially added to the formulations, ranging from 1.40 ± 0.02 mg 
WRPJĮ-T3 (Table 2B). HowevHUDVWKHDPRXQWRIHQWUDSSHGĮ-T3 increased, 
the IC50 of the formulations also gradually increased from 0.57 ± 0.26 µg/mL until it 
reaches a plateau from 4.98 ± 0.33 µg/mL (Table 2B). This demonstrates that the amount 
RI Į-T3 within the bilayer vesicle membrane has a marked impact on the activity of the 
formulation against cancer cell viability. 
 
3.3.3. Amount of transferrin conjugated to the vesicles 
The amount of transferrin conjugated to the vesicles increased linearly with increasing 
amounts of transferrin added to the formulation (6 mg, 12 mg, 18 mg, 24 mg or 30 mg Tf), 
until it reached a plateau following addition of 24 mg transferrin, for which the vesicle 
surface became saturated with conjugated transferrin (18.6 ± 0.4 mg conjugated Tf) (Table 
2C). Further increase in transferrin concentration marginally increased the amount of 
transferrin conjugated.  
As transferrin was added in increasing amounts, the percentage of ligand conjugation 
decreased gradually (from 86.7 ± 2.3 % to 64.2 ± 0.6 % respectively for 6 mg Tf to 30 mg 
Tf added to the vesicles). 
The IC50 YDOXHVRIDOOWKHIRUPXODWLRQVRQ$FHOOVZHUHEHORZȝJP/IURP
µg/mL to 0.92 ± 0.05 µg/mL) and did not appear to follow a trend relative to the amount of 
conjugated Tf. The formulation to which 12 mg transferrin was initially added showed a 
significantly lowest IC50 YDOXHRIȝJP/ 
 
3.3.4. Replacement of unilamellar vesicles by multilamellar vesicles 
0XOWLODPHOODUYHVLFOHVPDGHRI6SDQFKROHVWHURO73*6DQG'23(DQGHQWUDSSLQJĮ-
T3 were successfully prepared, as confirmed by TEM imaging (Fig. 2). The size of the 
multilamellar vesicles was significantly larger compared to that of Solulan C24-based 
unilamellar vesicles, with Tf-bearing vesicles being larger than control vesicles  
(respectively 176 ± 1 nm and 167 ± 1 nm for Tf-bearing and control vesicles) (Table 2D). 
Both Tf- and control vesicles were shown to be negatively charged, with zeta potentials of 
-52 ± 3 mV and -49 ± 2 mV respectively for Tf-bearing and control vesicles. 
The percentage of drug loading was 69.9 ± 0.2 %, similar to what observed with the 
unilamellar vesicles. However, the IC50 for these formulations was significantly much lower 
than with unilamellar vesicles (respectively 0.38 ± 0.07 µg/mL and 0.45 ± 0.06 µg/mL for 
Tf-bearing and control vesicles).  
 
 
 
Figure 2. Transmission electron micrograph images of Tf-bearing and control multilamellar 
vesicles enWUDSSLQJĮ-T3 (Bar: 100 nm). 
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3.4. Analysis of cellular uptake 
7KH FHOOXODU XSWDNH RI Į-T3 after treatment with Tf-bearing multilamellar vesicles was 
increased compared to control vesicles and the drug solution on A431 cell line (Fig. 3). In 
WHUPVRILQWUDFHOOXODUGLVWULEXWLRQ&$56H[SHULPHQWVVKRZHGWKDWĮ-T3 was disseminated 
within the nucleus and cytoplasm of A431 cells following administration of Tf-bearing 
YHVLFOHV%\FRQWUDVWĮ-T3 administered in control vesicles or as a solution could not be 
detected. This might be explained by the threshold of the technique that probably allowed 
only the most intense CARS signals to be analyzed. 
 
 
 
 
 
Figure 3.  CARS and transmission microscopy imaging of the cellular uptake of Į-T3 (0.2 
µg/well) either entrapped in Tf-vesicles, control vesicles or in solution, after incubation for 
12 hours in A431 cells. All images were taken in the size of 512 pixels x 512 pixels and 
with no averaging, at a frame capture rate of 1.68 s. The pump wavelength and the Stokes 
beam wavelength were tuned to 752.1 nm and 963.4 nm, corresponding to a Raman shift 
of 2916 cm-1 where the drug was expected to give the strongest CARS signals (bar: 50 
µm). 
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3.5. In vivo tumoricidal activity 
,QWUDYHQRXVO\ DGPLQLVWHUHG Į-T3 entrapped in Tf-bearing multilamellar vesicles led to 
tumor regression occurring within 24 hours on A431 tumors (Fig. 4A). This effect was 
maintained for 11 days, allowing the majority of the tumors to reach a size about half their 
initial size. From Day 11, while some tumors kept regressing, others started growing, 
which led to an overall slowdown of A431 tumor growth compared to the tumor growth 
observed with the other treatments. From Day 16, the mice bearing growing tumors 
reaching the maximum allowed size (13 mm) had to be euthanized. The other animals 
bearing smaller tumors were kept in the study. By contrast, none of the other treatments 
resulted in any A431 tumor regression. 
 
 
 
 
Figure 4. A) Tumor growth studies in a mouse A431 xenograft model after intravenous 
administration of Tf-bearing vesicles entrapping Į-T3 (10 µg/injection) (green). Controls:  
control vesicles entrapping Į-T3 (orange), Į-T3 solution (red), untreated tumors (black) 
(n=10). 
B) Variations of the animal body weight throughout the treatment (Color coding as in A). 
C) Overall tumor response to treatments at the end of the study (Day 30). 
D) Time to disease progression. The Y axis gives the proportion of surviving animals over 
time (Color coding as in A). 
 12 
 
A similar pattern of tumor growth was observed as well on B16-F10-OXF FHOOV Į-T3 
entrapped in intravenously administered Tf-bearing vesicles also led to tumor regression, 
but only for the first 3 days of the experiment (Fig. 5A). From Day 3, the treatment slowed 
growth overall compared to the other treatments, where tumor growth proceeded 
unchecked. From Day 14, the mice bearing tumors reaching the maximum allowed size 
(13 mm) had to be euthanized, while the others remained in the study. For this cell line as 
well, none of the other treatments resulted in tumor regression. 
 
 
 
Figure 5. A) Tumor growth studies in a mouse B16-F10 xenograft model after intravenous 
administration of Tf-bearing vesicles entrapping Į-T3 (10 µg/injection) (green). Controls:  
control vesicles entrapping Į-T3 (orange), Į-T3 solution (red), untreated tumors (black) 
(n=10). 
B) Variations of the animal body weight throughout the treatment (Color coding as in A). 
C) Overall tumor response to treatments at the end of the study (Day 30). 
D) Time to disease progression. The Y axis gives the proportion of surviving animals over 
time (Color coding as in A). 
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7KH WKHUDSHXWLF HIIHFW UHVXOWLQJ IURP WUHDWPHQW ZLWK Į-T3 entrapped in Tf-bearing 
multilamellar vesicles was also qualitatively confirmed by bioluminescence imaging (Fig. 
6). Following treatment with the Tf-bearing formulation, luciferase expression in the tumors 
gradually decreased from Day 1 to Day 7, whereas all the other treatments resulted in 
tumor growth. 
All the treatments were well tolerated by the mice, and no apparent signs of toxicity or 
weight loss were observed (Fig. 4B and Fig. 5B). 
On the last day of the experiment, 30% of A431 tumors and 60% of B16-F10-luc tumors 
treated with Tf-YHVLFOHVHQWUDSSLQJĮ-T3 had completely disappeared, while 20% of A431 
tumors and 10% of B16-F10 tumors showed a partial response (Fig. 4C and Fig. 5C). In 
addition, 10% of A431 tumors were stable following treatment with control vesicles. 
However, 100% RIWKHWXPRUVWUHDWHGZLWKĮ-T3 solution or left untreated were progressive 
for both tumor types. 
As a consequence of this enhanced therapeutic effect, animal survival was extended by 13 
and 15 days respectively for mice bearing A431 and B16-F10 tumors, compared to 
untreated mice (Fig. 4D and Fig. 5D). The injection of control vesicles also increased the 
survival of the treated mice by 7 and 9 days respectively for A431 and B16-F10 tumors, 
compared to untreated animals. 
 
 
Figure 6. Bioluminescence imaging of the tumoricidal activity of Į-T3 entrapped in Tf-
bearing vesicles in a mouse B16-F10-luc tumor model. Controls: control vesicles 
entrapping Į-T3, free Į-T3 drug in solution, untreated tumors. The scale indicates surface 
radiance (photons/s/cm2/steradian).  
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4. Discussion 
The use of the vitamin E tocotrienol for the treatment of cancer has so far been limited by 
the inability of this drug to specifically reach tumors following systemic injection. To 
overcome this issue, we hypothesized that entrapping only the most efficacious tocotrienol 
compound(s) within a tumor-targeted delivery system that has been optimized to enhance 
the anti-proliferative effect of the carried drug, would increase the therapeutic efficacy in 
vivo.  
Transferrin receptor is an attractive target for selective receptor-mediated drug delivery to 
tumors because of its overexpression on cancer cells, and has been widely used for 
tumor-targeted drug delivery [5,14]. In addition, the combination of transferrin-based active 
targeting with the passive targeting resulting from the enhanced permeability and retention 
effect [15] provides a tumor-selective targeting to this delivery system [16].  
Among the various formulations investigated, multilamellar vesicles conjugated to 12 mg 
Tf and entrapping 2 mg of Į-T3 were found to give the highest efficacy against A431 cell 
viability. These vesicles had a size lower than the cut-off size required for extravasation 
(which has been found to be 400 nm for most tumors [17,18]) and therefore have the 
required properties to access the transferrin receptor-expressing cancer cells and 
specifically deliver tocotrienol. In addition, their net negative charges would limit the risk of 
having electrostatic interactions between the vesicles and negatively charged cell 
membrane, therefore reducing any non-specific uptake of the vesicles by non-cancerous 
cells [19].    
The entrapment of the lipophilic tocotrienol within the lipidic membranes of the vesicles 
offers the opportunity to administer this drug intravenously while shielding it from 
degradation, thus ensuring sufficient circulating tocotrienol available for reaching the 
tumors. Besides, multilamellar vesicles present the advantage of an increased drug 
loading and shielding from degradation, subsequently improving the dosing regimen and 
therapeutic index. In our previous study, transferrin-bearing, tocopheryl-based 
multilamellar vesicles entrapping tocotrienol rich fraction were shown to improve the drug 
uptake by A431 and B16-F10 cells [9], leading to an enhanced efficacy against cell viability 
in vitro. However, the IC50 obtained with this TRF-based formulation (0.89 ± 0.11 µg/mL on 
A431 cells, 4.09 ± 0.65 µg/mL on B16-F10 cells) were much higher than those obtained 
ZLWKRXUFXUUHQWĮ-T3±based formulation, highlighting the crucial need of entrapping only 
the most active member of the Vitamin E family in optimized vesicles. We could not find 
any other studies describing the anti-proliferative effect of tocotrienol entrapped in 
liposomes, unilamellar or multilamellar vesicles on cancer cells to allow a comparison with 
our results. 
Among the various T3 and Toc compounds VWXGLHGĮ-T3 entrapped alone in Tf-bearing 
vesicles led to the highest efficacy against cancer cell viability. This result was 
XQH[SHFWHGDVĮ-T3 was often reported to be the least potent pro-apoptotic inducer in the 
literature, when compared to all the other tocotrienols [20]. Individual tocotrienols and 
tocopherols display differential potencies in suppressing tumor cell growth and inducing 
DSRSWRVLVGHSHQGLQJRIWKHFHOOOLQHVVWXGLHG)RUH[DPSOHĮ-7DQGȖ-T3 were shown to 
effectively suppress the development of sarcoma 180, Ehrlich carcinoma and invasive 
mammary carcinoma [21]. However, in DLD-1 human colorectal adenocarcinoma and 
+HS*KXPDQKHSDWRPDFHOOVĮ-T3 was the least effective among all T3 compounds [22]. 
6LPLODUO\LQDQRWKHUVWXG\Ȗ- DQGį-T3 reduced cell viability on SKBR3 and MCF-7 breast 
cancer cell lines with IC50 YDOXHVRIOHVVWKDQKDOIWKRVHRIĮ-T3 [23@Į-T3 also exhibited 
WKHOHDVWSRWHQWF\WRWR[LFLW\WRZDUGVERWK$DQG80*FHOOVFRPSDUHGWRį-7DQGȖ-
T3 [23]. However, the IC50 reported in these publications were obtained following treatment 
ZLWK Į-T3 solution, and were much higher than those REWDLQHG LQ RXU VWXG\ ZLWK Į-T3 
entrapped in targeted vesicles, thus demonstrating the need of a targeted delivery system 
to capture the full potential of the tocotrienol compound against cell viability.  
The presence of the lipophilic drug Į-T3 within the bilayer structure may influence the 
membrane characteristics of the vesicle. AVWKHDPRXQWRIHQWUDSSHGĮ-T3 increased, the 
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IC50 of the formulations increased gradually until it reached a plateau. This unexpected 
result indicates that changes in the amounW RI Į-T3 entrapped within the bilayer vesicle 
membrane have a marked impact on the in vitro activity of the formulation against cell 
viability by modifying physicochemical characteristics that may have altered its cellular 
permeability, uptake and efficacy. 
The IC50 values changed in irregular fashion with respect to the conjugated amount of 
transferrin or amount of entrapped drug. However, it is interesting to note that the 
formulation with the highest drug entrapment efficacy also resulted in the lowest IC50 value 
in A431 cell line, although formulations with higher amounts of transferrin were assessed. 
These results indicate that obtaining an optimum amount of transferrin conjugation and an 
optimum drug entrapment within the vesicles is a major factor to enhance the activity of 
the formulation against cancer cell viability. 
Cellular uptake studies demonstrated that the conjugation of Tf to the vesicles significantly 
increased Į-T3 uptake by A431 cells, compared with control vesicles and tocotrienol 
solution. These results were in agreement with our previous experiments that showed that 
the presence of Tf on similar vesicles enhanced the uptake of TRF by at least 1.5-fold for 
the same cell line [9]. 
In vivo, we demonstrated that the intravenous administratiRQRIĮ-T3 entrapped within Tf-
bearing vesicles resulted in complete tumor eradication for 30% of A431 and 60% of B16-
F10 tumors, and partial tumor regression for 20% of A431 cells and 10% of B16-F10 cells. 
This work corresponds to a major improvement of the therapeutic efficacy of this drug for 
the treatment of distant tumors. As far as we know, this work corresponds to the first 
preparation of a tumor-targeted delivery system able to entrap a single tocotrienol. Other 
researchers have previously demonstrated the ability of TRF co-entrapped with 
simvastatin in lipid nanoparticles to have an enhanced anti-proliferative effect against +SA 
PDPPDU\HSLWKHOLDOFDQFHUFHOOOLQHLQFRPSDULVRQZLWKFRQWUROĮ-tocopherol nanoparticles 
(with respective IC50 of 0.52 µM and 17.7 µM), but only in vitro and while using TRF rather 
than a tocotrienol compound [24]. The therapeutic effects observed in this current study 
were even more pronounced than those obtained in our previous studies with Tf-bearing 
multilamellar vesicles entrapping TRF, which resulted in tumor eradication of 20% of A431 
tumors and 40% of B16-F10 tumors [9], and with Tf-bearing unilamellar vesicles 
entrapping TRF, which led to complete disappearance of 20% of A431 and 50% of B16-
F10 cells [7]. This demonVWUDWHVWKHDELOLW\RIĮ-T3 to exert an anti-cancer effect in vivo on 
the tested cancer cell lines, provided it is targeted to the tumors. Furthermore, this 
intravenously administered nanomedicine was able to act upon subcutaneously implanted 
tumors and should therefore have the potential to target metastatic tumors disseminated 
throughout the body. 
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5. Conclusions 
In this study, we have demonstrated for the first time that D QRYHO IRUPXODWLRQ RI Į-T3 
entrapped in tumor-targeted vesicles can lead to complete tumor eradication for up to 60% 
of the tested tumors, following intravenous administration.  
Among the various formulations investigated, multilamellar vesicles conjugated to 12 mg 
Tf and entrapping 2 mg of Į-T3 were found to give the highest efficacy against A431 
cancer cell viability in vitro. 
In vivo, Į-T3 entrapped in Tf- bearing multilamellar vesicles resulted in complete tumor 
suppression for 60% of B16-F10 tumors and 30% of A431 tumors, with long-term survival 
of the animals. By contrast, 100% of the tumors treated with the tocotrienol solution or left 
untreated were progressive for both tumor types. Animal survival was improved by more 
than 13 days compared to controls. The treatments were well tolerated by the animals. 
Transferrin-bearing vesicles entrapping Į-T3 therefore hold great potential as a novel 
approach for cancer therapy.  
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